A Phase 1/2 interventional study of Oral 13 cis retinoic acid and Aerosolized 13 cis retinoic acid in Covid19 Vaccine, sponsored by Kafrelsheikh University. Status unknown. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-02.
Sponsored by Kafrelsheikh University · Phase 1/2, Interventional, and Prevention
Investigating the role of 13cis retinoic acid in the treatment of COVID-19 and enhancement of Its spike protein based vaccine efficacy and safety.
The study is an urgent randomized interventional comparative Phase II trial for investigating the expected long term side effects of spike protein based vaccine which may vary from thrombosis, platelet aggregation, autoantibodies against ACE2, to lung damage and other ACE2 expressing cell damage. This clinical study is conducted on 360 adult male and female participants, Here, we submitted this clinical trial depending on studies with up to date literature guidance to indicate that 13 cis Retinoic Acid will provide complete protection against COVID-19 and will be better option for effective and safe COVID-19 vaccine owing to its ability to induce mucosal IgA antibodies that are less prone to ADE phenomenon and responsible for passive mucosal immunity in the respiratory tract. Retinoic acid strengthens mucosal immunity via inducing IgA antibodies and considered potent IgA isotype Furthermore, its impact on ACE2 receptors, Memory T cells, CD4+/CD8+ ratio, Neutrophil Chetnotaxis, Interferon Type1, Thrombin, Transmembrane serine protease 2 (TMPRSS2), toll-like receptor 3 (TLR3), mitochondrial antiviral-signaling protein (MAVS), papain-like protease (PLpro), and Interleukin 6 ( Il-6).
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
The SARS-CoV-2 spike protein directly binds with the host cell surface Angiotensin-converting enzyme 2 (ACE2) facilitating virus entry, invading and replication.[1][5][6][7][8][9][10].Further analysis even suggested that COVID-19 recognizes human ACE2 more efficiently than SARS-CoV increasing the ability of COVID-19 to transmit from human to human [11][12] Upregulation of human ACE2 enhanced and induced disease severity in a mouse model of SARS-CoV infection, demonstrating that viral entry into cells is a critical step[13][14] Receiving Vaccine based on COVID-19 spike protein may increase the risk of Cellular ACE2 autoimmunity via production of autoantibodies . Many studies demonstrated that autoimmune response to Angiotensin-converting enzyme 2 ( ACE2) induced by forced presentation of the ACE2 protein in a complex with CoV Spike protein in Fc Receptor positive Antigen Presenting Cells in the lung [3][4] According to this we hypothesis that spike proteins produced by Vaccine based on the spike protein which would potentially bind to the elevated levels of soluble ACE2 enzyme. This complex of spike protein with multiple soluble ACE2 enzymes which is similar to COVID-19 binding with cellular and soluble ACE2 will be presented to macrophages to highlight antigens for antibody production. It is very possible that Abs will be produced that target the Angiotensin Converting Enzyme 2 of host cells enzyme. The combination of the virus spike protein or vaccine spike protein with the soluble ACE2 receptor becomes antigenic, which may cause the formation of antibodies against not only the virus spike protein or vaccine spike protein , but also parts of the ACE and ACE2 receptor. Therefore we hypothesize that Vaccines based on the spike protein might initiate Autoantibodies and T cells to ACE2 via binding of spike protein particles produced by vaccine with its receptors ACE2 and The development of autoantibodies to ACE2 might make damage to the host epithelial cell in lungs and the other different organs which express ACE2 in lung, heart and kidney would lead to inflammation at those sites. This pattern of lung injury also occurs in Pulmonary Hypertension secondary to Scleroderma with elevated levels of anti ACE2 antibodies.[73][78].In addition, we expect that any drug upregulation of ACE2 as in diabetic and hypertensive patients will increase the risk of autoantibodies in case of immunization by Vaccine based on the COVID-19 spike protein. As a result we think that covid-19 vaccine developer should use a suitable ACE2 modulator to decrease this possible risk via helping in formation of antibodies targeting spike protein not antibodies targeting ACE2 and spike protein complex which may increase the risk of cellular ACE2 auto antibodies , The COVID-19 vaccine may be altered each year to counter changes to circulating strains therefore, the possible risk of cellular ACE2 damage by autoantibodies produced by vaccine based on COVID-19 vaccine may increase with vaccination .After searching, we found a study analyzed a broad set of 672 clinically approved drugs for treatment in cell lines demonstrated that isotretinoin was the potent and strongest downregulator of Angiotensin-converting enzyme 2 (ACE2) receptors [15] and further, studies reported that it may prevent the cellular entry of SARS-CoV-2 and can be a taken as a targeted therapy in COVID-19 [16][17][18]. The primary isomers of RA formed in vivo are 9-cis-retinoic acid (9cRA) and All-trans-Retinoic Acid (atRA) and; each binds separate RA receptor types, thus acting upon a select subset of genes [76]. 13cRA is a synthetic form that may function similar to the other produced isoforms, or by isomerization to atRA and 9c RA. Although the exact mechanism of action is unclear; in other words, therefore we hypothesis that isotretinoin binds directly to ACE2 receptors and leads to its downregulation via blocking ACE2 binding capacity and this mechanism may lead to block of COVID-19 binding to cellular and soluble ace2 receptors
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 360 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Kafrelsheikh University is the lead sponsor of 285 studies on the registry; 110 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The competent physician considered it inappropriate to participate in the study
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Safety and promising features of isotretinoin in tne era of COVID 2019 according Principal Investigator Protocol:
The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
Drug: Oral 13 cis retinoic acid
The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days. All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.
Drug: Aerosolized 13 cis retinoic acid
The participants will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
Combination Product: 13 cis retinoic acid doses orally in combination with spike protein based vaccine
The participants will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
Combination Product: Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine
The participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants will have 15 routine visits over a 24 month period.All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented
Biological: Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days
Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day
Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
Dose of 5-7.5x10\^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
Assess the efficacy of the candidate oral and aerosolized isotretinoin for providing complete protection against COVID-19 in adults aged 18 years and older.
Occurrence of COVID-19 infection
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Assess the safety of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in adults aged 18 years and older.
Occurrence of expected serious side effects throughout the study duration and in the duration of followup: 1. Generation of Autoantibodies against host ACE2 2. Platelets aggregation 3. Thrombosis 4. Lung damage and fibrosis 5. Sexual problems 6. Neurological problems
Time frame: Time Frame: Study duration (24 months from last vaccination) ]
Assess the efficacy of the candidate vaccine spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine for providing complete protection against COVID-19 in adults aged 18 years and older.
Occurrence of COVID-19 infection
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Assess the efficacy of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 combined with oral and aerosolized isotetinoin in adults aged 18 years and older. for providing complete protection against COVID-19
Occurrence of COVID-19 infection
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Assess the safety of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in combination with oral or aersolized 13 cis retinoic acid in adults aged 18 years and older.
Occurrence of expected serious side effects throughout the study duration and in the duration of followup: 1. Generation of Autoantibodies against host ACE2 2. Platelets aggregation 3. Thrombosis 4. Lung damage and fibrosis 5. Sexual problems 6. Neurological problems
Time frame: Time Frame: Study duration (24 months from last vaccination) ]
Assess efficacy of the candidate oral and aerosolized isotretinoin against COVID-19
Number of intensive care unit (ICU) admissions associated with COVID-19
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Assess efficacy of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine against COVID-19
Number of intensive care unit (ICU) admissions associated with COVID-19
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Assess safety of the candidate spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine combined with oral and aerosolized isotetinoin in vaccinated participants
Number of intensive care unit (ICU) admissions associated with COVID-19
Time frame: Time Frame: Study duration (48 months from last vaccination) ]
Assessment the expression of MDAP-5 , RIG-1 , IFN1, TLR3 and IFN1 in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Absolute lymphocyte counts (CD4,CD8 and CD25+FOXP3+ Regulatory T cells ) in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Assessment the generated IgA antibodies in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Thrombin
Thrombin time (TT) Isotretinoin therapy has furthermore proven anti-inflammatory, anti-platelet and fibrinolytic activities. which may protect participants from widespread blood clots in case of infection with covid-19
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Assessment the expression of Transe membrane protease ,serine II (TMPRSS2) changes over time in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Assessment the expression of Angiotensin-converting enzyme II (ACE2) changes over time in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Time frame: Time Frame: Study duration (12 months from last dose donation ) ]
Platelet aggregation in Isotretinoin treated participants in comparison with vaccinated participants with spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Time frame: Time Frame: Study duration (24 months from last vaccination) ]
ACE2 autoantibodies IgG and IgM
Time frame: Time Frame: Study duration (24 months from last vaccination) ]
No study locations are listed for this record.
This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kafrelsheikh University